BiotechTube
MagQu

MagQu

Taipei, United States· Est.
magqu.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

MagQu is a diagnostics company built on its patented ImmunoMagnetic Reduction (IMR) technology, which enables picoscale, highly sensitive detection of biomarkers in blood. Its core focus is on developing and commercializing assays for Alzheimer's disease (detecting Aβ-40, Aβ-42, and Tau proteins) and cancers like liver and colorectal cancer. The company is commercial-stage, with ISO and GMP certifications, TFDA approvals for its analyzers, and a growing international sales footprint across Asia, Europe, and the US.

Alzheimer's DiseaseNeurological DisordersLiver CancerColorectal Cancer

Technology Platform

ImmunoMagnetic Reduction (IMR) - An ultra-sensitive, label-free immunoassay technology that detects picoscale biomarkers by measuring the reduction in AC magnetic susceptibility of magnetic reagent beads upon target binding.

Opportunities

The global push for early, blood-based biomarkers in Alzheimer's disease represents a massive, underserved market where MagQu's ultra-sensitive IMR technology is highly differentiated.
Additionally, the growing demand for custom magnetic beads and OEM services in life sciences provides a scalable, diversified revenue stream alongside its core IVD business.

Risk Factors

Key risks include the regulatory uncertainty and high cost of obtaining CE-IVD and FDA approvals for its assays in major markets.
The company also faces intense competition from large diagnostic firms and alternative technology platforms, and must overcome the market adoption challenge for a novel detection methodology.

Competitive Landscape

MagQu competes in the high-sensitivity immunoassay segment against platforms like Quanterix's SIMOA and Merck's SMCxPRO. In Alzheimer's diagnostics, it faces competition from established CSF assays, emerging blood-based tests from companies like C2N Diagnostics and Roche, and amyloid PET imaging. Its magnetic bead services compete with large suppliers like Thermo Fisher Scientific and Merck.

More companies in Diagnostics & Precision Medicine →More companies in United States →